Objective： To study the common single nucleotide polymorphism （SNPs） of sulphonylurea receptor 1 （SUR1） gene （16-3c/t and S1369A） and its relationship with the glucose-reducing effect of gliclazide. Methods; A total of 115 patients with type 2 diabetes were enrolled in this 8-week, open-label, cohort study. All patients were required to take gliclazide for 8 weeks. FPG, HbAlc and insulin were assayed before and after therapy and HOMA-B and HOMA IR indices were calculated to assess the therapeutic effects of gliclazide. The gene polymorphism of SUR1 was analyzed by Taq-Man technology and the effects of gliclazide were compared between patients with different phenotypes. Restults： （1） The study was completed in 101 of the 115 patients and the frequencies of c and t alleles were 0.54 and 0.44, A and S were 0.58 and 0.42, respectively. （2） FPG, HbAlc and HOMA B indices were significantly improved after therapy in patients with all kinds of genotypes （P~0. 05）; HOMA-IR indices had no significant change after therapy（P〉0.05）. （3） The changes of HbAlc and HOMAB indices of t/t group were more obvious than those of c/c and c/t groups （P〈0.05）. S1369A polymorphism had no association with the effect of gliclazide（P〉0.05）. Conclusion： The polymorphism of SUR1 can influence the glucose-reducing effect of gliclazide and this influence might be associated with loci of SNPs.[著者文摘]